CA-125 monitored therapy with GnRH analogue of pelvic endometriosis.
Thirteen patients affected by endometriosis have been treated with GnRH analogue Buserelin. CA-125 serum levels have been monitored before, during and after treatment. Analysis of data suggests the hypothesis of an individualized follow up by means of repeated assays of CA-125 and their reference to pre and post treatment graphs.
Negri
P
P
Clinica Ostetrica e Ginecologica, Università di Ferrara.
Ricciardelli
M A
MA
Tomasi
A
A
Grechi
E
E
Fortini
R M
RM
D000328:Adult; D000704:Analysis of Variance; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D002064:Buserelin / Q000009:adverse effects / Q000627:therapeutic use*; D004715:Endometriosis / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008597:Menstrual Cycle / Q000378:metabolism; D010386:Pelvic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D011374:Progesterone / Q000097:blood
D015295:Antigens, Tumor-Associated, Carbohydrate; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin